Brighter receives final approvals for pilot research with insulin-treated diabetes patients in the UAE
Brighter AB (Publ) (“Brighter” or “The Company”) today announces that it has received ethical approval for the research pilot in the United Arab Emirates. The approval is granted by the country's Ministry of Health and Prevention’s (MoHAP) research ethics committee.
The approval marks the last local requirement that was needed to start the pilot. What remains now is to finalize the training of the healthcare providers, and then start onboarding patients.
In addition to the ethical approval, the UAE Ministry of Health has also granted Brighter import-clearance approval.
Pilot projects of this kind are essential for Brighter in order to confirm the benefits that Actiste® brings to people with diabetes in a local setting. The UAE study is a high-level pilot project that the company hopes will confirm the fit of Actiste® in the local setting, and pave the way for a subsequent roll out to more patients on a commercial basis.
“The upcoming UAE pilot project is one of several significant achievements for the company this year,” says Brighter CEO, Erik Lissner. “We have already started one study in the UK, and the first patients are recruited there. The data generating process is one of the most critical steps in building the body of clinical evidence for Actiste®.”
Brighter is planning to continue conducting user-experience pilots and clinical-research studies, and believes that the scientific community will continue to be interested in testing how Actiste® may address unmet needs in the management of diabetes.
For further information, please contact:
Investor Relations
ir@brighter.se
Certified Adviser
Brighter’s Certified Adviser är Mangold Fondkommission AB,
+46 8 5277 5020, ca@mangold.se, www.mangold.se.
About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is a key to providing smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones, and their care providers – aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter's quality management system is ISO-13485 certified. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.
For more information, please visit our website at https://brighter.se/.